EGMN -- Daily subcutaneous injections of nesiritide led to significant improvements in left ventricular volume in a placebo-controlled pilot study with 40 heart failure patients treated for 8 weeks.
EGMN -- Daily subcutaneous injections of nesiritide led to significant improvements in left ventricular volume in a placebo-controlled pilot study with 40 heart failure patients treated for 8 weeks.